Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

W Arpornwirat,I Albert,Vincent L. Hansen,M. A. Russo,G. A. Ross,C. D. Pence,R. R. Bandekar,Steven M. Grunberg

Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

2006

W Arpornwirat
I Albert
Vincent L. Hansen
M. A. Russo
G. A. Ross
C. D. Pence
R. R. Bandekar
Steven M. Grunberg

8512 Background: Casopitant mesylate is a potent, selective, oral NK-1 RA, which has shown activity in preventing CINV in preclinical studies. Based on phase I positron emission tomography (PET) st...

Keywords:

Antagonist
Nausea
Ondansetron
Chemotherapy
Anesthesia
CASOPITANT MESYLATE
Vomiting
Medicine
Tachykinin receptor 1
Pathology
Gastroenterology
Positron emission tomography
group trial
Casopitant
Internal medicine
Pharmacology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations